Wed Sep 25 03:50:46 UTC 2024: ## Hedge Funds Are Bullish on Amicus Therapeutics: Is It Time to Buy?

**Amicus Therapeutics (FOLD), a biotechnology company developing treatments for rare diseases, is attracting the attention of hedge funds.**

The company’s stock has been performing poorly, down 52% year-to-date, despite the launch of its Pompe disease treatment earlier this year. The competition, particularly Sanofi’s Nexviazyme, is seen as a major threat, with the larger company possessing more resources for marketing and distribution.

However, hedge funds remain optimistic about Amicus’s potential, ranking it among the top guru stocks to buy. This is driven by the company’s focus on rare diseases, a high-growth sector with significant market potential.

Amicus’s management remains confident in the performance of their Pompe treatment, with a strong global launch and increasing patient uptake. They also highlighted the continued success of their Fabry disease treatment, Galafold, launched eight years ago.

**While Amicus is considered a strong investment opportunity, analysts believe that certain AI stocks offer even higher potential returns.**

The article encourages readers to explore AI stocks, specifically highlighting the “cheapest AI stock” available in a separate report. It also suggests that the Guru ETF, which tracks the holdings of top hedge funds, presents an alternative approach to investing in these high-conviction stocks.

**Overall, Amicus Therapeutics remains a promising investment for those seeking exposure to the biotechnology sector, particularly those seeking high-growth potential in rare diseases.**

However, investors should carefully consider the competitive landscape and the potential risks associated with this investment.

Read More